Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next

The quarterly results for Indegene Limited (NSE:INDGN) were released last week, making it a good time to revisit its performance. Results overall were respectable, with statutory earnings of ₹17.02 per share roughly in line with what the analysts had forecast. Revenues of ₹8.0b came in 5.6% ahead of analyst predictions. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus from Indegene's seven analysts is for revenues of ₹32.6b in 2026. This would reflect a modest 7.4% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to rise 6.9% to ₹19.86. In the lead-up to this report, the analysts had been modelling revenues of ₹32.6b and earnings per share (EPS) of ₹19.52 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for Indegene

There were no changes to revenue or earnings estimates or the price target of ₹633, suggesting that the company has met expectations in its recent result. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Indegene analyst has a price target of ₹700 per share, while the most pessimistic values it at ₹540. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Indegene's past performance and to peers in the same industry. The analysts are definitely expecting Indegene's growth to accelerate, with the forecast 15% annualised growth to the end of 2026 ranking favourably alongside historical growth of 12% per annum over the past year. Compare this with other companies in the same industry, which are forecast to grow their revenue 17% annually. Indegene is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Indegene analysts - going out to 2028, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.